Friday, 14 Jun 2019

You are here

The RheumNow Week in Review – We’re Number One! (8.17.18)

Dr. Cush reviews the articles and news from the last week on RheumNow.com. Information on comorbidities, the downside of steroids, unmet need in psoriatic arthritis, and the top 10 rheumatology programs.

  1. Does Hep C cause RA? Claims data from Taiwan looked at HCV pts and found the risk of developing RA to be lower in those treated with interferon based therapy (HR 0.63 (95% CI 0.43 to 0.94, p=0.023). vs. untreated https://t.co/gEYlnPWMTb
  2. Australian Rheumatology Database comparison shows that psoriatic arthritis patients had greater odds of depression (OR 2.1), hypertension (1.7), hyperlipidemia (2.0), diabetes (2.2) & ischemic heart disease (2.0). https://t.co/ZUwUAJmUIV
  3. RA patients who develop lung cancer are more likely to be diagnosed at an advanced stage and have a poorer performance scores & are less likely to receive surgery, radiotherapy, chemotherapy or targeted therapy. https://t.co/Fre8pQQ0bL
  4. Study of UK Clinical Practice Research Database shows that in #RA, steroid use assoc w/ increased risk of diabetes (OR 1.33), OP (1.41) thrombotic stroke or MI (1.28), serious infection (1.28), & death (1.33), with many of these being dose related https://t.co/RDxwpLByFA
  5. Managing Comorbidity and Poor Drug Responses
  6. There is no association between rising MCV levels and hematologic toxicity of methotrexate https://t.co/CcNfyKrTb2
  7. Data from a prospective longitudinal cohort of PsA patients shows that greater Xray damage is associated with exposure to prolonged repetitive hand movements and occupations with higher level of finger dexterity https://t.co/4yrAIPFKnK
  8. Unmet need in Psoriatic Arthritis! 10 Yr study of 331 PsA pts from Norway shows no increase in remission rates, no signif change in PRO's and no increase in DMARD or biologic use. Large need for T2T remission in PsA. https://t.co/dbZGyavXfY
  9. Early Exposure to Passive Smoke May Up Risk for RA Later in Life   
  10. Tumor Necrosis Factor Inhibitors Do Not Increase the Risk of Cancer Recurrence  
  11. U.S. News 2018-19 Rheumatology Rankings 
  12. Drugs causing a metallic taste? Antibiotics (including tetracycline and amoxicillin), lithium (used to treat psychiatric disorders), certain cardiac medications, and allopurinol (which treats gout and kidney stones)  

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Ultrasound Reveals Which Anti-CCP Positive Patients Progress to Arthritis 

Power Doppler signal on baseline ultrasound exam may well help stratify anti-CCP positive patients with musculoskeletal symptoms but no clinical synovitis, according to data from the Leeds Institute of Rheumatic and Musculoskeletal Medicine presented at EULAR 2019.

EULAR 2019 – Day 3 Report

The third day of EULAR 2019 started with novel biologics, the efficacy of secukinumab in axial psoriatic arthritis, neurologic events with TNF inhibitors from the DANBIO database (OP0261), and neuropathy in SLE (OP0252), but above all this was a big poster day. Here are selected highlights from day 3 EULAR in Madrid.

RheumNow Podcast – EULAR 2019 Streamin' - (6.14.19)

Dr. Jack Cush reports from Madrid on several novel presentations from EULAR 2019.

1. Genovese Vagal nerve stimulator in RA

2. Low dose steroids in Hand OA

EULAR 2019 Report – Day 2

It was a full and lively 2nd day in Madrid with sessions dedicated to Lupus, RA, Sjogren’s, imaging, rare diseases, psoriatic arthritis and spondyloarthritis. Here are a few of the highlights from day 2 EULAR in Madrid 

Be ‘on point’: Guidelines for rheumatic complications of immunotherapy

At EULAR 2019, Madrid, several recommendations including RA, SLE, and Sjogren’s syndrome have been developed.